HCV NATs for Organ-Donor Screening Angela M. Caliendo, MD, PhD Professor and Vice Chair Pathology and Laboratory Medicine Emory University School of Medicine

First Page		Document Content
Date: 2012-02-15 09:31:07 Chiron Corporation Novartis Nucleic acid test Assay Medicine Viral load HIV test Chemistry HIV/AIDS Science		HCV NATs for Organ-Donor Screening Angela M. Caliendo, MD, PhD Professor and Vice Chair Pathology and Laboratory Medicine Emory University School of Medicine Add to Reading List Source URL: www.cdc.gov Download Document from Source Website File Size: 399,03 KB Share Document on Facebook

	Applied Proteomics Appoints Erwin Estigarribia as Vice President, Commercial Operations SAN DIEGO – May 07, 2015 -‐ Applied P DocID: 1r1cm - View Document
	Australian start-up Chiron Global receives Series B funding Australian-based company Chiron Global, parent company of Unified Weapons Master (UWM), today announced that it has secured Series B funding from an unnamed hig DocID: 11KLY - View Document
	AABB 53rd Annual M.eeting November 7,200O Multiplex NAT Reactive Donor Specimens Tested Non-Reactive in Discriminatory Assays are DocID: S3BQ - View Document
	Microsoft PowerPoint[removed]Swiss Export Day Kim Stratton - final.pptx DocID: OWkO - View Document
	L A B O R A T O R Y Technical Bulletin August 3, 2009 DocID: N8D0 - View Document